60 Degrees Pharmaceuticals Files 8-K

TL;DR

60 Degrees Pharma filed an 8-K for financial statements/exhibits. No major news.

AI Summary

On July 25, 2024, 60 Degrees Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns the company's financial statements and exhibits, indicating a reporting event rather than a specific transaction or material development. No specific dollar amounts or new business initiatives were detailed in the provided excerpt.

Why It Matters

This filing indicates that 60 Degrees Pharmaceuticals, Inc. is providing updated financial information or exhibits to the SEC, which is a standard regulatory requirement.

Risk Assessment

Risk Level: low — The filing is a routine 8-K for financial statements and exhibits, not indicating any immediate material changes or risks.

Key Players & Entities

• 60 DEGREES PHARMACEUTICALS, INC. (company) — Registrant
• July 25, 2024 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of Incorporation
• 001-41719 (identifier) — Commission File Number
• 45-2406880 (identifier) — IRS Employer Identification Number
• 1025 Connecticut Avenue NW , Suite 1000 Washington , D.C. 20036 (address) — Registrant's principal executive office

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 SXTP The Nasdaq Stock Market LLC
• $311,862 — at it was awarded a contract, valued at $311,862, with the United States Army Medical Ma

Filing Documents

• ea021010701-8k_60degrees.htm (8-K) — 29KB
• ea021010701ex99-1_60degrees.htm (EX-99.1) — 14KB
• image_001.jpg (GRAPHIC) — 6KB
• 0001013762-24-001604.txt ( ) — 273KB
• sxtp-20240725.xsd (EX-101.SCH) — 4KB
• sxtp-20240725_def.xml (EX-101.DEF) — 26KB
• sxtp-20240725_lab.xml (EX-101.LAB) — 36KB
• sxtp-20240725_pre.xml (EX-101.PRE) — 25KB
• ea021010701-8k_60degrees_htm.xml (XML) — 6KB

01. Other Events

Item 8.01. Other Events. On July 25, 2024, 60 Degrees Pharmaceuticals, Inc. (the "Company") issued a press release announcing that it was awarded a contract, valued at $311,862, with the United States Army Medical Materiel Development Activity to facilitate commercial validation of a new bottle and replacement blister packaging of ARAKODA (tafenoquine), the Company's U.S. Food and Drug Administration-approved product indicated for malaria prevention. This initiative is critical for ensuring the continued procurement by the U.S. government. The information set forth under this Item 8.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

01 Financial Statements

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. The following exhibits are being filed herewith: Exhibit No. Description 99.1 Press Release of 60 Degrees Pharmaceuticals, Inc. dated as of July 25, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: July 26, 2024 60 DEGREES PHARMACEUTICALS, INC. By: /s/ Geoffrey Dow Name: Geoffrey Dow Title: Chief Executive Officer and President

View Full Filing

View this 8-K filing on SEC EDGAR